AKT1 and hepatocellular carcinoma: These findings suggest that resistance to Sorafenib is mediated by the activation of the PI3K/AKT signaling pathway, and inhibiting this pathway can reverse resistance in HCC cells (YJ et al., 2017; H et al., 2018).